Un characterized protein C16orf90 (ISOform A) as a potential drug target and biomarker

Target Name: C16orf90

NCBI ID: G646174

C16orf90

Un characterized protein C16orf90 (ISOform A) as a potential drug target and biomarker

Abstract:
C16orf90 (ISOform A) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and various functions make it an attractive target for drug development. This article aims to provide an overview of C16orf90, its functions, and potential as a drug target and biomarker.

Introduction:
C16orf90 is a protein that is located on chromosome 16 and is characterized by its unique isoform A form. It is a member of the superfamily of proteins known as X-linked myristoylated proteins (SMPs) and is involved in various cellular processes, including cell signaling, protein synthesis, and intracellular transport. C16orf90 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, C16orf90 has gained significant interest as a potential drug target and biomarker.

Function and interactions:
C16orf90 is involved in the regulation of various cellular processes, including cell signaling, protein synthesis, and intracellular transport. It plays a role in the regulation of myristoylated protein (MyP) synthesis, which is a critical step in the synthesis of proteins and is often impaired in various diseases, including cancer. C16orf90 is also involved in the regulation of protein degradation and has been shown to play a role in the detoxification of damaged proteins.

In addition to its role in cellular processes, C16orf90 is also involved in the regulation of various signaling pathways. It has been shown to play a role in the regulation of T-cell signaling, which is crucial for the immune response and has been implicated in various diseases, including cancer. C16orf90 is also involved in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs.

Potential as a drug target:
C16orf90's unique structure and various functions make it an attractive target for drug development. Its involvement in the regulation of cellular processes and its role in various diseases make it an potential candidate for drug targeting. Additionally, its isoform A form makes it different from other SMPs, which could provide unique benefits in drug development.

Potential as a biomarker:
C16orf90 has also been shown to have potential as a biomarker for various diseases, including cancer. Its unique isoform A form and its involvement in the regulation of cellular processes make it an potential indicator of disease status. Additionally, its involvement in the regulation of MyP synthesis and protein degradation make it an potential biomarker for cancer.

Conclusion:
C16orf90 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and various functions make it an attractive target for drug development. Additionally, its potential as a biomarker for various diseases makes it an important step in the development of new treatments. Further research is needed to fully understand the functions and potential of C16orf90 as a drug target and biomarker.

Protein Name: Chromosome 16 Open Reading Frame 90

The "C16orf90 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C16orf90 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets